Analysis of genetic samples from China appears to link the COVID-19 pandemic’s origin to raccoon dogs; FDA commissioner Robert Califf calls on private insurers to invest more in clinical drug research; BioXcel files for cancer subsidiary OnkoXcel to go public.
Five things for pharma marketers to know: Friday, March 17, 2023
External advisors to the Food and Drug Administration recommend full approval of Paxlovid; The Alzheimer’s Association lobbies for Medicare coverage of Leqembi; Pfizer recalls millions of Nurtec ODT prescription drugs.
Five things for pharma marketers to know: Thursday, March 16, 2023
Mediar Therapeutics raises $85 million to develop drugs for diseases that cause scarring in organs; Bellicum Pharmaceuticals halted its Phase I/II trials after a serious adverse event; The Food and Drug Administration says Paxlovid is not associated with COVID rebound.
Five things for pharma marketers to know: Wednesday, March 15, 2023
Amgen sued over hiding $10.7 billion in taxes and penalties; GSK reveals positive Phase III data for meningococcal vaccine; Switch Therapeutics makes debut with $52 million in funding.
Five things for pharma marketers to know: Tuesday, March 14, 2023
Carl Icahn prepares for proxy fight at Illumina; Falling biotech stocks bode ill for broad economy; Federal health officials warn parents about what they should know about properly sterilizing breast pump equipment.
Five things for pharma marketers to know: Monday, March 13, 2023
Reflecting on the COVID-19 pandemic three years later; Moderna to hire 2,000 new employees and add new West Coast offices by end of 2023; Novartis CEO Vas Narasimhan brought home 25% less in pay last year.
Five things for pharma marketers to know: Friday, March 10, 2023
Bayer plans to spend $1 billion on U.S. pharma research and development this year; Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz; Scientists revive a ‘zombie’ virus that spent 48,500 years frozen in permafrost.
Five things for pharma marketers to know: Thursday, March 9, 2023
The House Select Subcommittee on the Coronavirus Pandemic holds first hearing; COVID-19 lab leak fight obscures the global rise of high-security biolabs; Bindi Irwin shares her endometriosis diagnosis in an effort to raise awareness.
Five things for pharma marketers to know: Wednesday, March 8, 2023
Biden proposes extending Medicare price negotiations to more drugs; WeightWatchers jumps into prescription weight loss drug market with acquisition of Sequence; Rapport Therapeutics launches with $100 million from Third Rock, Johnson & Johnson.
Five things for pharma marketers to know: Tuesday, March 7, 2023
French CAR-T biotech Mnemo Therapeutics shutters its U.S. operations; Merck’s experimental heart drug sotatercept boosts exercise capacity in hypertension patients; MMR vaccine rates lag due to discredited study.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix